An article in the November issue of the American Journal of Medicine reports that a study of almost 400,000 COPD and asthma patients showed a 34% increase in the rate of Type 2 diabetes among those using inhaled corticosteroid (ICS). Higher doses of ICS were associated with higher increased risk of developing diabetes. The study was conducted by researchers from the Lady Davis Institute for Medical Research at Jewish General Hospital in Montreal, Canada. Read the abstract.
Study shows increased risk of diabetes with ICS use
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
